ЖурналыПодпискаАрхивКнигиПроектыО насРекламаДоставка/ОплатаКонтакты
+7 (495) 482-43-29
  • Главная
  • / Журналы
  • / Вернуться в журнал
  • / Содержание номера
  • / Статья
Актуальность проблемы тугоухости у детей с муковисцидозом (обзор литературы)

Актуальность проблемы тугоухости у детей с муковисцидозом (обзор литературы)

Авторы:
Андрей Иванович Крюков,
Алексей Юрьевич Ивойлов,
Нейля Адельшиновна Милешина,
Надежда Сергеевна Данилевская,
Михаил Михайлович Полунин,
Ольга Игоревна Симонова,
Кирилл Леонидович Мещеряков,
Вера Николаевна Соколова,
Наталия Юрьевна Каширская,
Рена Абульфазовна Зинченко,
Виктория Валерьевна Бариляк

Журнал: Вестник оториноларингологии. 2026;91(1):41-49.

DOI: 10.17116/otorino20269101141

Прочитано: 1011 раз

Резюме

Процесс нарушения слуха у детей с муковисцидозом остается одной из актуальных научно-практических проблем. В статье рассмотрено влияние системной терапии антибиотиками аминогликозидного ряда на слуховую функцию детей, больных муковисцидозом.

ЦЕЛЬ ИССЛЕДОВАНИЯ

Проанализировать причины тугоухости и изучить зависимость поражения слуховой функции у детей с муковисцидозом от антибактериальной терапии антибиотиками аминогликозидного ряда.

МАТЕРИАЛ И МЕТОДЫ

Поиск литературных источников осуществлен с помощью поисковых механизмов баз данных PubMed, Web of Science и eLibrary.

РЕЗУЛЬТАТЫ

Обзор данных литературы показывает, что острая проблема нейросенсорной тугоухости связана с частым приемом аминогликозидов, а предикторами кондуктивной тугоухости являются воспалительные процессы в среднем ухе и евстахиевой трубе. Не во всех случаях антибактериальная терапия антибиотиками аминогликозидного ряда приводит к нарушению слуха, что означает острую необходимость изучения слуховой функции у детей с муковисцидозом и выявления особенностей нарушения слуха.

Ключевые слова

  • муковисцидоз
  • аминогликозиды
  • нейросенсорная тугоухость
  • кондуктивная тугоухость
  • нарушение слуха у детей

Дата поступления: 22.04.2025

Дата принятия в печать: 22.08.2025

Дата публикации: 01.03.2026

Литература / References
  1. Каширская Н.Ю., Капранов Н.И., Кондратьева Е.И. Муковисцидоз. Монография. Издание 2-е, переработанное и дополненное. М.: Медпрактика; 2021.
  2. Garinis AC, Poling GL, Rubenstein RC, Konrad-Martin D, Hullar TE, Baguley DM, Burrows HL, Chisholm JA, Custer A, Hawe LD, Hunter LL, Marras TK, Ortiz CE, Petersen L, Steyger PS, Winthrop K, Zettner EM, Clark K, Hungerford M, Vachhani JJ, Brewer CC. Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients with Cystic Fibrosis. American Journal of Audiology. 2021;30(3S):800-809. https://doi.org/10.1044/2021_aja-21-00031
  3. Scotet V, L’Hostis C, Férec C. The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes. 2020;11(6):589. https://doi.org/10.3390/genes11060589
  4. Wu M, Davis JD, Zhao C, Daley T, Oliver KE. Racial inequities and rare CFTR variants: impact on cystic fibrosis diagnosis and treatment. Journal of Clinical and Translational Endocrinology. 2024;36:100344. https://doi.org/10.1016/j.jcte.2024.100344
  5. Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis. 2022;21(3):456-462. https://doi.org/10.1016/j.jcf.2022.01.009
  6. Sosnay PR, Raraigh KS, Gibson RL. Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator: Genotype and Phenotype. Pediatric Clinics of North America. 2016;63:585-598. https://doi.org/10.1016/j.pcl.2016.04.002
  7. Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, Sommerburg O, Accurso FJ, Davies JC, Rock MJ, Sanders DB, Wilschanski M, Sermet-Gaudelus I, Blau H, Gartner S, McColley SA. Diagnosis of Cystic Fibrosis in Screened Populations. The Journal of Pediatrics. 2017;181S:S33-S44. https://doi.org/10.1016/j.jpeds.2016.09.065
  8. Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, Radojkovic D, Rizzotti P, Schwarz M, Stuhrmann M, Tzetis M, Zielenski J, Elborn JS. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. Journal of Cystic Fibrosis. 2008;7:179-196. https://doi.org/10.1016/j.jcf.2008.03.009
  9. Регистр больных муковисцидозом в Российской Федерации. 2017 год. М.: Медпрактика-М; 2019.
  10. Petrova NV, Kashirskaya NY, Vasilyeva TA, Timkovskaya EE, Voronkova AY, Shabalova LA, Kondratyeva EI, Sherman VD, Novoselova OG, Kapranov NI, Zinchenko RA, Ginter EK, Makaov AKh, Kerem B. High prevalence of W1282x mutation in cystic fibrosis patients from Karachay-Cherkessia. Journal of Cystic Fibrosis. 2016;15:e28-e32. https://doi.org/10.1016/j.jcf.2016.02.003
  11. Petrova NV, Kashirskaya NY, Saydaeva DK, Polyakov AV, Adyan TA, Simonova OI, Gorinova YV, Kondratyeva EI, Sherman VD, Novoselova OG, Vasilyeva TA, Marakhonov AV, Macek M Jr, Ginter EK, Zinchenko RA. Spectrum of CFTR mutations in Chechen cystic fibrosis patients: High frequency of c.1545_1546delTA (p.Tyr515X; 1677delTA) and c.274G>A (p.Glu92Lys, E92K) mutations in North Caucasus. BMC Medical Genetics. 2019;20:44. https://doi.org/10.1186/s12881-019-0785-z
  12. Paranjapye A, Ruffin M, Harris A, Corvol H. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. Journal of Cystic Fibrosis. 2020;19(Suppl 1):S10-S14. https://doi.org/10.1016/j.jcf.2019.11.001
  13. Bobadilla J L, Macek M, Jr, Fine J P, Farrell P M. Cystic fibrosis: a worldwide analysis of CFTR mutations — correlation with incidence data and application to screening. Human Mutation. 2002;19(6):575-606. https://doi.org/10.1002/humu.10041
  14. Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, Algire M, McWilliams R, Beck S, Hoover-Fong J, Hamosh A, Cutler D, Cutting GR. Heritability of lung disease severity in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 2007;175(10):1036-1043. https://doi.org/10.1164/rccm.200608-1164OC
  15. Knowles MR, Drumm M. The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harbor Perspectives in Medicine. 2012;2(12):009548. https://doi.org/10.1101/cshperspect.a009548
  16. Mafficini A, Ortombina M, Sermet-Gaudelius I, Lebecque P, Leal T, Iansa P, Reychler G, Dahan K, Pepermans X, Lenoir G, Leonard A, Sorio C, Assael B, Melotti P. Impact of polymorphism of multidrug resistance-associated protein 1 (ABCC1) gene on the severity of cystic fibrosis. Journal of Cystic Fibrosis. 2011;10(4):228-233. https://doi.org/10.1016/j.jcf.2010.10.007
  17. Ideozu JE, Zhang X, Pan A, Ashrafi Z, Woods KJ, Hessner MJ, Simpson P, Levy H. Increased expression of plasma-induced ABCC1 mRNA in cystic fibrosis. International Journal of Molecular Sciences. 2017;18(8):1752. https://doi.org/10.3390/ijms18081752
  18. Yokoyama E, Chávez-Saldaña M, Orozco L, Cuevas F, Lezana JL, Vigueras-Villaseñor RM, Rojas-Castañeda JC, Landero DA. Influence of SNPs in genes that modulate lung disease severity in a group of Mexican patients with cystic fibrosis. Archives of Medical Research. 2018;49(1):18-26. https://doi.org/10.1016/j.arcmed.2018.04.010
  19. Marson FA, Bertuzzo CS, Ribeiro AF, Ribeiro JD. Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis. BMC Pulmonary Medicine. 2012;12:50. https://doi.org/10.1186/1471-2466-12-50
  20. Marson FAL, Bertuzzo CS, Hortencio TDR, Ribeiro JD, Bonadia LC, Ribeiro AF. The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis. BMC Pulmonary Medicine. 2012;12(1):41. https://doi.org/10.1186/1471-2466-12-41
  21. Gong J, Wang F, Xiao B, Panjwani N, Lin F, Keenan K, Avolio J, Esmaeili M, Zhang L, He G, Soave D, Mastromatteo S, Baskurt Z, Kim S, O’Neal WK, Polineni D, Blackman SM, Corvol H, Cutting GR, Drumm M, Knowles MR, Rommens JM, Sun L, Strug LJ. Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci. PLoS Genetics. 2019;15(2):e1008007. https://doi.org/10.1371/journal.pgen.1008007
  22. Sofia VM, Surace C, Terlizzi V, Da Sacco L, Alghisi F, Angiolillo A, Braggion C, Cirilli N, Colombo C, Di Lullo A, Padoan R, Quattrucci S, Raia V, Tuccio G, Zarrilli F, Tomaiuolo AC, Novelli A, Lucidi V, Lucarelli M, Castaldo G, Angioni A. Trans-heterozygosity for mutations enhances the risk of recurrent/chronic pancreatitis in patients with cystic fibrosis. Molecular Medicine. 2018;24(1):38. https://doi.org/10.1186/s10020-018-0041-6
  23. Smith DJ, Klein K, Hartel G, Wainwright CE, Bell SC, Anderson GJ, Reid DW. Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis. Gene. 2019;683:12-17. https://doi.org/10.1016/j.gene.2018.10.002
  24. Henderson LB, Doshi VK, Blackman SM, Naughton KM, Pace RG, Moskovitz J, Knowles MR, Durie PR, Drumm ML, Cutting GR. Variation in MSRA modifies risk of neonatal intestinal obstruction in cystic fibrosis. PLoS Genetics. 2012;8(3):e1002580. https://doi.org/10.1371/journal.pgen.1002580
  25. Boëlle PY, Debray D, Guillot L, Corvol H, French CF. Modifier Gene Study Investigators SERPINA1 Z allele is associated with cystic fibrosis liver disease. Genetics in Medicine. 2019;21(9):2151-2155. Epub 2019 Feb 11. PMID: 30739910. https://doi.org/10.1038/s41436-019-0449-6
  26. Boëlle PY, Debray D, Guillot L, Clement A, Corvol H, French CF. Modifier Gene Study Investigators Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology. 2019;69(4):1648-1656. https://doi.org/10.1002/hep.30148
  27. Strug LJ, Gonska T, He G, Keenan K, Ip W, Boëlle PY, Lin F, Panjwani N, Gong J, Li W, Soave D, Xiao B, Tullis E, Rabin H, Parkins MD, Price A, Zuberbuhler PC, Corvol H, Ratjen F, Sun L, Bear CE, Rommens JM. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Human Molecular Genetics. 2016;25(20):4590-4600. PMID: 28171547; PMCID: PMC5886039. https://doi.org/10.1093/hmg/ddw290
  28. Клинические рекомендации. Кистозный фиброз (муковисцидоз). 2021. Ссылка активна на 22.12.25. https://disuria.ru/_ld/11/1113_kr21E84MZ.pdf
  29. Chen Q, Shen Y, Zheng J. A review of cystic fibrosis: Basic and clinical aspects. Animal Models and Experimental Medicine. 2021; 4(3):220-232. https://doi.org/10.1002/ame2.12180
  30. Леденева Л.Н., Водовозова Э.В., Григорьянц И.С., Белаш Т.А., Енина Е.А., Пустабаева М.С. Роль неонатального скрининга в диагностике и выявляемости муковисцидоза в Ставропольском крае. Российский вестник перинатологии и педиатрии. 2021;66(4):290-291.
  31. Cystic Fibrosis Foundation. Patient Registry Annual Data Report. 2017. Accessed December 22, 2025. https://www.researchgate.net/figure/Cystic-Fibrosis-Foundation-Patient-Registry-2017-Annual-Data-Report-Bethesda-Maryland_fig1_344366258
  32. Conway SP, Miller MG, Ramsden C, Littlewood JM. Intensive treatment of pseudomonas chest infection in cystic fibrosis: A comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta Pediatrica. 1985;74(1):107-113. https://doi.org/10.1111/j.1651-2227.1985.tb10929.x
  33. Barclay ML, Begg EJ, Chambers ST, Thornley PE, Pattemore PK, Grimwood K. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy. 1996;37(6):1155-1164. https://doi.org/10.1093/jac/37.6.1155
  34. Zettner EM, Gleser MA. Progressive hearing loss among patients with cystic fibrosis and parenteral aminoglycoside treatment. Otolaryngology — Head and Neck Surgery. 2018;159(5):887-894. Epub 2018 Jun 19. PMID: 29914288. https://doi.org/10.1177/0194599818782444
  35. Besser J, Festen JM, Goverts ST, Kramer SE, Pichora-Fuller MK. Speech-in-speech listening on the LiSN-S test by older adults with good audiograms depends on cognition and hearing acuity at high frequencies. Ear and Hearing. 2015;36(1):24-41. https://doi.org/10.1097/AUD.0000000000000096
  36. Heffner HE, Heffner RS. High-frequency hearing. In: Dallos P, Oertel D, Hoy R, eds. Handbook of the Senses: Audition. Elsevier; 2008:55-60. https://doi.org/10.1016/B978-012370880-9.00004-9
  37. Hirsch I, Davis H, Silverman S, Reynolds E, Eldert E, Benson R. Development of materials for speech audiometry. Journal of Speech and Hearing. 1952;17(3):321-337. https://doi.org/10.1044/jshd.1703.321
  38. Jiang M, Karasawa T, Steyger PS. Aminoglycoside-induced cochleotoxicity: A review. Frontiers in Cellular Neuroscience. 2017 Oct 09; 11:308. https://doi.org/10.3389/fncel.2017.00308
  39. Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clinical Pharmacology and Therapeutics. 2017;102(3): 459-469. https://doi.org/10.1002/cpt.726
  40. Cutting GR, Engelhardt J, Zeitlin PL. Genetics and Pathophysiology of Cystic Fibrosis. In: Kendig’s Disorders of the Respiratory Tract in Children. Amsterdam, the Netherlands: Elsevier; 2019:757-768.
  41. Lazrak A, Fu L, Bali V, Bartoszewski R, Rab A, Havasi V, Keiles S, Kappes J, Kumar R, Lefkowitz E. The silent codon change I507-ATC→ ATT contributes to the severity of the ΔF508 CFTR channel dysfunction. FASEB Journal. 2013;27(11):4630-4645. Epub 2013 Aug 01. PMID: 23907436; PMCID: PMC4046180. https://doi.org/10.1096/fj.13-227330
  42. Espel JC, Palac HL, Bharat A, Cullina J, Prickett M, Sala M, McColley SA, Jain M. The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype. Journal of Cystic Fibrosis. 2018 Jan;17(1):34-42. Epub 2017 Dec 06. PMID: 29221674. https://doi.org/10.1016/j.jcf.2017.11.002
  43. Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Frontiers in Pharmacology. 2020;10:1662. https://doi.org/10.3389/fphar.2019.01662
  44. Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC. CFTR modulator theratyping: Current status, gaps and future directions. Journal of Cystic Fibrosis. 2019;18:22-34. https://doi.org/10.1016/j.jcf.2018.05.004
  45. Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Pharmacology and Therapeutics. 2015;145:19-34. https://doi.org/10.1016/j.pharmthera.2014.06.005
  46. Li Q, Liu S, Ma X, Yu J. Effectiveness and Safety of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Children with Cystic Fibrosis: A Meta-Analysis. Frontiers in Pediatrics. 2022;10:937250. https://doi.org/10.3389/fped.2022.937250
  47. Elborn JS, Blasi F, Burgel P-R, Peckham D. Role of inhaled antibiotics in the era of highly effective CFTR modulators. European Respiratory Review. 2023;32(167):220154. https://doi.org/10.1183/16000617.0154-2022
  48. Taylor-Cousar JL, Robinson PD, Shteinberg M, Downey DG. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Lancet. 2023;402(10408):1171-1184. Epub 2023 Sep 09. PMID: 37699418. https://doi.org/10.1016/s0140-6736(23)01609-4
  49. Hwang T-C, Yeh J-T, Zhang J, Yu Y-C, Yeh H-I, Destefano S. Structural mechanisms of CFTR function and dysfunction. Journal of General Physiology. 2018;150:539-570. https://doi.org/10.1085/jgp.201711946
  50. Bernard A, Hermans C, Dom G, Terryn S, Leal T, Lebecque P, Cassiman J-J, Scholte BJ, de Jonge HR, Courtoy PJ. Cystic fibrosis is associated with a defect in apical receptor–mediated endocytosis in mouse and human kidney. Journal of the American Society of Nephrology. 2007;18:707-718. https://doi.org/10.1681/ASN.2006030269
  51. Raggi C, Fujiwara K, Leal T, Jouret F, Devuyst O, Terryn S. Decreased renal accumulation of aminoglycoside reflects defective receptor-mediated endocytosis in cystic fibrosis and Dent’s disease. Pflugers Archiv: European Journal of Physiology. 2011;462:851-860. https://doi.org/10.3389/fphar.2019.01662
  52. Ramananda Y, Naren AP, Arora K. Functional Consequences of CFTR Interactions in Cystic Fibrosis. International Journal of Molecular Sciences. 2024;25:3384. https://doi.org/10.3390/ijms25063384
  53. Levring J, Chen J. Structural identification of a selectivity filter in CFTR. Proceedings of the National Academy of Sciences of the United States of America. 2024 Feb 27;121(9):e2316673121. Epub 2024 Feb 21. PMID: 38381791; PMCID: PMC10907310. https://doi.org/10.1073/pnas.2316673121
  54. Kopp R, Krautloher A, Ramírez-Fernández A, Nicke A. P2X7 interactions and signaling: making head or tail of it. Frontiers in Molecular Neuroscience. 2019;12:183. https://doi.org/10.3389/fnmol.2019.00183
  55. Alves LA, de Melo Reis RA, de Souza CA, de Freitas MS, Teixeira PC, Neto Moreira Ferreira D, Xavier RF. The P2X7 receptor: Shifting from a low- to a high-conductance channel — an enigmatic phenomenon? Biochimica et Biophysica Acta. 2014; 1838(10): 2578-2587. https://doi.org/10.1016/j.bbamem.2014.05.015
  56. Gabillard-Lefort C, Casey M, Glasgow AMA, Boland F, Kerr O, Marron E, Lyons AM, Gunaratnam C, McElvaney NG, Reeves EP. Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2022; 205(7):783-794. https://doi.org/10.1164/rccm.202106-1426oc
  57. Al-Malky G, Suri R, Dawson SJ, Sirimanna T, Kemp D. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions. International Journal of Audiology. 2011;50(2):112-122. https://doi.org/10.3109/14992027.2010.524253
  58. Thomsen J, Friis B, Jensen K, Bak-Pedersen K, Larsen PK. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis. Journal of Antimicrobial Chemotherapy. 1979;5(3):257-260. https://doi.org/10.1093/jac/5.3.257
  59. Scheenstra RJ, Heijerman HG, Zuur CL, Touw DJ, Rijntjes E. No hearing loss after repeated courses of tobramycin in cystic fibrosis patients. Acta Oto-Laryngologica. 2010 Feb;130(2):253-258. PMID: 19479457. https://doi.org/10.3109/00016480903015150
  60. Garinis AC, Cross CP, Srikanth P, Carroll K, Feeney MP, Keefe DH, Hunter LL, Putterman DB, Cohen DM, Gold JA, Steyger PS. The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. Journal of Cystic Fibrosis. 2017;16(3):401-409. https://doi.org/10.1016/j.jcf.2017.01.006
  61. Поляков Д.П., Дайхес Н.А., Базанова М.В., Мельяновская Ю.Л. Оценка риска патологии слуха при муковисцидозе у детей. Вестник оториноларингологии. 2024;89(3):29-35. https://doi.org/10.17116/otorino20248903129
  62. Forman-Franco B, Abramson AL, Gorvoy JD, Stein T. Cystic fibrosis and hearing loss. Archives of Otolaryngology — Head and Neck Surgery. 1979;105(6):338-342. https://doi.org/10.1001/archotol.1979.00790180036007
  63. Stavroulaki P, Vossinakis IC, Dinopoulou D, Doudounakis S, Adamopoulos G, Apostolopoulos N. Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Archives of Otolaryngology — Head and Neck Surgery. 2002;128(2):150-155. https://doi.org/10.1001/archotol.128.2.150
  64. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrobial Agents and Chemotherapy. 1987;31(4):594-599. https://doi.org/10.1128/AAC.31.4.594
  65. Martins L, Camargos PA, Becker HM, Becker CG, Guimaraes RE. Hearing loss in cystic fibrosis. International Journal of Pediatric Otorhinolaryngology. 2010;74(5):469-473. https://doi.org/10.1016/j.ijporl.2010.01.021
  66. Schneider-Futschik EK, Munro CB, Quinlan C, Ranganathan S. Investigating the Potential Hearing Impairment and Ototoxicity in Children up to Six Years With Cystic Fibrosis After Aminoglycoside Exposure (PIANO‐CF Extension). Pediatric Pulmonology. 2025;60(2):27505. https://doi.org/10.1002/ppul.27505
  67. Harruff EE, Kil J, Ortiz MGT. Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation. Journal of Cystic Fibrosis. 2021;20(2):288-294. https://doi.org/10.1016/j.jcf.2020.11.020
  68. Gleser MA, Zettner EM. Negative Hearing Effects of a Single Course of IV Aminoglycoside Therapy in Cystic Fibrosis Patients. International Journal of Audiology. 2018;57(12):923-930. https://doi.org/10.1080/14992027.2018.1514537
  69. Aminoglycoside. In: Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Aronson JK, ed. 15th ed. Vol. 1. The Netherlands: Elsevier; 2006:118-136.
  70. Kahlmeter G, Dahlager JI. Aminoglycoside Toxicity — A Review of Clinical Studies Published between 1975 and 1982. Journal of Antimicrobial Chemotherapy. 1984;13(Suppl A):9-22. https://doi.org/10.1093/jac/13.suppl_a.9
  71. Massie J, Cranswick N. Pharmacokinetic Profile of once Daily Intravenous Tobramycin in Children with Cystic Fibrosis. Journal of Paediatrics and Child Health. 2006;42(10):601-605. https://doi.org/10.1111/j.1440-1754.2006.00944.x
  72. WHO. Programme for the Prevention of Deafness and Hearing Impairment. In: Report of An Informal Consultation on Strategies for Prevention of Hearing Impairments from Ototoxic Drugs. 1995:21-23.
slide-cover
slide-cover
slide-cover

Рекомендуем статьи по данной теме:

Применение аппаратной высокочастотной осцилляции грудной стенки с фокусной пульсацией (Respin 11) в комплексной терапии тяжелого обострения муковисцидоза.Респираторная медицина. 2026;2(2):61-65

Биофизические механизмы мукостаза в дыхательных путях и их моделирование: роль осмотического баланса и модели «гель на щетке».Респираторная медицина. 2026;2(2):41-46

Новости молекулярной биологии: дайджест научных публикаций. Выпуск 4.Лабораторная служба. 2026;15(2):5-7

История использования CFTR-модуляторов при терапии муковисцидоза.Респираторная медицина. 2025;1(3):40-50

Синоназальная патология у пациентов с первичной цилиарной дискинезией.Российская ринология. 2025;33(3):223-232

Влияние адекватной коррекции слуховой функции на когнитивную функцию.Вестник оториноларингологии. 2025;90(4):105-111

Болезнь Меньера и вестибулярная мигрень: дифференциальная диагностика и лечение.Вестник оториноларингологии. 2025;90(1):57-63

Дерматологические заболевания, предрасполагающие к развитию наружного отита (обзор литературы).Вестник оториноларингологии. 2025;90(1):50-56

Редкий наследственный синдром Сиддики с новыми психоневрологическими проявлениями.Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(12):171-176

Ототоксичность, обусловленная приемом противоэпилептических препаратов.Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(12):14-19

Издательство «Медиа Сфера»
РекламаДоставка/ОплатаО насКонтактыОбучение для редакцийПолитика конфиденциальностиПолитика обработки персональных данныхПубличная оферта на реализацию издательской продукции
ЖурналыПодпискаАрхивКнигиПроекты
  • RuStore

© 1998-2026

  • Телефоны издательства:

  • +7 (495) 482-41-18
  • +7 (495) 482-43-29

  • Прямой телефон отдела подписки
    (только по вопросам заказов и доставки журналов)

  • +7 (800) 250-18-12

  • пн-пт с 10:00 до 18:00

  • Telegram
  • VK
info@mediasphera.ru

  • Почтовый адрес:

  • Издательство «Медиа Сфера»,
    а/я 54, Москва, Россия, 127238

  • RuStore

© 1998-2026